Real-world Research And Decision Tree Model Analysis Of Bismuth Quadruple Therapy For Helicobacter Pylori Eradication

Part one cost-effectiveness analysis of four treatment options for Helicobacter pylori eradication in Liaoning Objectives: Helicobacter pylori infection is a common public health problem today and is closely related to the incidence of many diseases.This study combines clinical data from a large comprehensive tertiary hospital in Liaoning,China to evaluate the pharmacoeconomics of the four currently used treatment options for Helicobacter pylori eradication,and to provide a reference for the selection of clinical treatment options for Helicobacter pylori infection.Methods: Based on retrospective analysis and research,a cost-effectiveness analysis of four treatment options for Helicobacter pylori eradication commonly used in a large comprehensive tertiary hospital from January 2017 to December 2018,and related sensitivity analysis.Results: The results of the study showed that "esmeprazole(20 mg,bid)+ amoxicillin(1000 mg,bid)+ furazolidone(100 mg,bid)+ bismuth potassium citrate(220 mg,bid),14d" compared with other treatment options It has a relatively satisfactory therapeutic effect in eradicating Helicobacter pylori and has more pharmacoeconomic value.The sensitivity analysis results are consistent with the research results.Conclusion: Bismuth quadruple therapy can effectively eradicate Helicobacter pylori,in which "esmeprazole(20 mg,bid)+ amoxicillin(1000 mg,bid)+ furazolidone(100 mg,bid)+ bismuth potassium citrate(220 mg,bid),14d" has better treatment effect and has higher drug economics.Part two cost-effectiveness analysis of four treatment strategies for Helicobacter pylori eradication in China based on decision tree modelsObjectives: This study is based on the research published in China at present,and through the construction of a decision tree model,specific pharmacoeconomic analysis of the four bismuth treatment schemes recommended in the "Fifth National Consensus Report on Helicobacter Pylori Infection Treatment" in China To provide a reference for clinical rational drug use.Methods: Through the construction of a decision tree model,the pharmacoeconomic evaluation of the four commonly used treatment options for Helicobacter pylori eradication recommended in our guidelines.Results: The results of the study showed that "esmeprazole(20 mg,bid)+ amoxicillin(1000 mg,bid)+ clarithromycin(500 mg,bid)+ bismuth potassium citrate(220 mg,bid),14 d "treatment was the best,with a H.pylori eradication rate of 92.8%(95% CI: 0.909-0.948).The results of pharmacoeconomic analysis show that,compared with other treatment options,"esomeprazole(20 mg,bid)+ amoxicillin(1000 mg,bid)+ furazolidone(100 mg,bid)+ bismuth potassium citrate(220 mg,bid),10 d ”was the superior solution,and the sensitivity analysis results were consistent with the results of pharmacoeconomic evaluation.Conclusion: Compared with other treatment options,"esomeprazole(20 mg,bid)+ amoxicillin(1000 mg,bid)+ furazolidone(100 mg,bid)+ bismuth potassium citrate(220 mg,bid),10d" plan is more economical,and it is recommended to give priority consideration when selecting a treatment plan in the clinic.